Long non‑coding RNA PCAT6 regulates bladder cancer progression via the microRNA‑143‑3p/PDIA6 axis

Zhang,Yuanjie; Chen,Lin; Luo,Gang

doi:10.3892/etm.2021.10379

Long non‑coding RNA PCAT6 regulates bladder cancer progression via the microRNA‑143‑3p/PDIA6 axis

Authors:
- Yuanjie Zhang
- Lin Chen
- Gang Luo
View Affiliations

Affiliations: Department of Urology, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: July 1, 2021 https://doi.org/10.3892/etm.2021.10379
Article Number: 947
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although long non‑coding (lnc)RNAs have been reported to be involved in the pathological development of bladder cancer, the functions of lncRNA prostate cancer‑associated transcript 6 (PCAT6) and its underlying mechanism of action in bladder cancer remain unknown. The present study aimed to investigate the effect of PCAT6 in bladder cancer progression and explore its potential application as a novel treatment target. The expression of PCAT6 and miR‑143‑3p in bladder cancer tissues, adjacent normal tissues and cell lines was measured using reverse transcription‑quantitative PCR. Fluorescence in situ hybridization assay was used to detect the subcellular localization of PCAT6. MTT, EdU, Transwell and wound healing assays were conducted to assess the biological function of PCAT6 on cell proliferation, migration and invasion. Putative binding sites between miR‑143‑3p and PCAT6 or PDIA6 were predicted using starBase, Lncbase and TargetScan analyzes. Dual‑luciferase reporter assay was also used to confirm the potential binding between PCAT6 and miR‑143‑3p. RNA immunoprecipitation assay was performed to verify the possible interaction between PCAT6 and miR‑143‑3p. Western blotting was used to measure the expression of PDIA6. The results demonstrated that the expression levels of PCAT6 were upregulated in bladder cancer tissues relative to those in adjacent normal bladder tissues. Knockdown of PCAT6 served a role in suppressing the proliferation, migration and invasion of T24T and EJ bladder cancer cells. PCAT6 knockdown contributed to a reduction of PDIA6 expression at the mRNA and protein levels compared with that in negative control‑transfected cells, whilst the miR‑143‑3p inhibitor partially mitigated this reduction effect. In addition, rescue experiments revealed that the miR‑143‑3p inhibitors reversed the effects of PCAT6 silencing on the malignant phenotypes of bladder cancer. Collectively, the results of the present study demonstrated that PCAT6 may serve an oncogenic role in bladder cancer via the miR‑143‑3p/PDIA6 axis. These results may provide a potential therapeutic target for the treatment of bladder cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
2	Dettlaff K, Stawny M, Ogrodowczyk M, Jelińska A, Bednarski W, Wątróbska-Świetlikowska D, Keck RW, Khan OA, Mostafa IH and Jankun J: Formulation and characterization of EGCG for the treatment of superficial bladder cancer. Int J Mol Med. 40:329–336. 2017.PubMed/NCBI View Article : Google Scholar
3	Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 71:447–461. 2017.PubMed/NCBI View Article : Google Scholar
4	Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, et al: NCCN guidelines insights: Bladder cancer, version 2.2016. J Natl Compr Canc Netw. 14:1213–1224. 2016.PubMed/NCBI View Article : Google Scholar
5	Mohammed AA, El-Tanni H, El-Khatib HM, Mirza AA, Mirza AA and Alturaifi TH: Urinary bladder cancer: Biomarkers and target therapy, new era for more attention. Oncol Rev. 10(320)2016.PubMed/NCBI View Article : Google Scholar
6	Babjuk M: Bladder cancer in the elderly. Eur Urol. 73:51–52. 2018.PubMed/NCBI View Article : Google Scholar
7	Batista PJ and Chang HY: Long noncoding RNAs: Cellular address codes in development and disease. Cell. 152:1298–1307. 2013.PubMed/NCBI View Article : Google Scholar
8	Isin M and Dalay N: LncRNAs and neoplasia. Clin Chim Acta. 444:280–288. 2015.PubMed/NCBI View Article : Google Scholar
9	Wang M, Guo C, Wang L, Luo G, Huang C, Li Y, Liu D, Zeng F, Jiang G and Xiao X: Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription. Cell Death Dis. 9(238)2018.PubMed/NCBI View Article : Google Scholar
10	Liu D, Li Y, Luo G, Xiao X, Tao D, Wu X, Wang M, Huang C, Wang L, Zeng F and Jiang G: LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer Lett. 388:281–291. 2017.PubMed/NCBI View Article : Google Scholar
11	Orom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, et al: Long noncoding RNAs with enhancer-like function in human cells. Cell. 143:46–58. 2010.PubMed/NCBI View Article : Google Scholar
12	Shi R, Wu P, Liu M, Chen B and Cong L: Knockdown of lncRNA PCAT6 Enhances radiosensitivity in triple-negative breast cancer cells by regulating miR-185-5p/TPD52 axis. Onco Targets Ther. 13:3025–3037. 2020.PubMed/NCBI View Article : Google Scholar
13	Dong D, Lun Y, Sun B, Sun H, Wang Q, Yuan G and Quan J: Silencing of long non-coding RNA PCAT6 restrains gastric cancer cell proliferation and epithelial-mesenchymal transition by targeting microRNA-15a. Gen Physiol Biophys. 39:1–12. 2020.PubMed/NCBI View Article : Google Scholar
14	Ma Z, Gu G, Pan W and Chen X: LncRNA PCAT6 accelerates the progression and chemoresistance of cervical cancer through up-regulating ZEB1 by sponging miR-543. Onco Targets Ther. 13:1159–1170. 2020.PubMed/NCBI View Article : Google Scholar
15	Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ and Epstein JI: Non-invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathol Int. 60:1–8. 2010.PubMed/NCBI View Article : Google Scholar
16	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017.PubMed/NCBI View Article : Google Scholar
17	Zheng F, Wang M, Li Y, Huang C, Tao D, Xie F, Zhang H, Sun J, Zhang C, Gu C, et al: CircNR3C1 inhibits proliferation of bladder cancer cells by sponging miR-27a-3p and downregulating cyclin D1 expression. Cancer Lett. 460:139–151. 2019.PubMed/NCBI View Article : Google Scholar
18	Liu F, Zhang H, Xie F, Tao D, Xiao X, Huang C, Wang M, Gu C, Zhang X and Jiang G: Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis. Oncogene. 39:1696–1709. 2020.PubMed/NCBI View Article : Google Scholar
19	Li Y, Zheng F, Xiao X, Xie F, Tao D, Huang C, Liu D, Wang M, Wang L, Zeng F and Jiang G: CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep. 18:1646–1659. 2017.PubMed/NCBI View Article : Google Scholar
20	Jiang G, Wu AD, Huang C, Gu J, Zhang L, Huang H, Liao X, Li J, Zhang D, Zeng X, et al: Isorhapontigenin (ISO) inhibits invasive bladder cancer formation in vivo and human bladder cancer invasion in vitro by targeting STAT1/FOXO1 axis. Cancer Prev Res (Phila). 9:567–580. 2016.PubMed/NCBI View Article : Google Scholar
21	Carlevaro-Fita J and Johnson R: Global positioning system: Understanding long noncoding RNAs through subcellular localization. Mol Cell. 73:869–883. 2019.PubMed/NCBI View Article : Google Scholar
22	Chen LL: Linking long noncoding RNA localization and function. Trends Biochem Sci. 41:761–772. 2016.PubMed/NCBI View Article : Google Scholar
23	Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y and Kassouf W: Bladder cancer. Lancet. 388:2796–2810. 2016.PubMed/NCBI View Article : Google Scholar
24	Guo Y, Chen D, Su X, Chen J and Li Y: The lncRNA ELF3-AS1 promotes bladder cancer progression by interaction with Kruppel-like factor 8. Biochem Biophys Res Commun. 508:762–768. 2019.PubMed/NCBI View Article : Google Scholar
25	Wang F, Zu Y, Zhu S, Yang Y, Huang W, Xie H and Li G: Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression. Biochem Biophys Res Commun. 507:231–235. 2018.PubMed/NCBI View Article : Google Scholar
26	Guan X, Xu Y and Zheng J: Long non-coding RNA PCAT6 promotes the development of osteosarcoma by increasing MDM2 expression. Oncol Rep. 44:2465–2474. 2020.PubMed/NCBI View Article : Google Scholar
27	Wu H, Zou Q, He H, Liang Y, Lei M, Zhou Q, Fan D and Shen L: Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. Cancer Med. 8:2484–2495. 2019.PubMed/NCBI View Article : Google Scholar
28	Bai F, Zhang N, Fang W, He X, Zheng Y and Gu D: PCAT6 mediates cellular biological functions in gastrointestinal stromal tumor via upregulation of PRDX5 and activation of Wnt pathway. Mol Carcinog. 59:661–669. 2020.PubMed/NCBI View Article : Google Scholar
29	Yu X, Wang ZL, Han CL, Wang MW, Jin Y, Jin XB and Xia QH: LncRNA CASC15 functions as an oncogene by sponging miR-130b-3p in bladder cancer. Eur Rev Med Pharmacol Sci. 23:9814–9820. 2019.PubMed/NCBI View Article : Google Scholar
30	Zhou K, Yang J, Li X and Chen W: Long non-coding RNA XIST promotes cell proliferation and migration through targeting miR-133a in bladder cancer. Exp Ther Med. 18:3475–3483. 2019.PubMed/NCBI View Article : Google Scholar
31	Wang F, Zu Y, Huang W, Chen H, Xie H and Yang Y: LncRNA CALML3-AS1 promotes tumorigenesis of bladder cancer via regulating ZBTB2 by suppression of microRNA-4316. Biochem Biophys Res Commun. 504:171–176. 2018.PubMed/NCBI View Article : Google Scholar
32	Ramos FS, Serino LT, Carvalho CM, Lima RS, Urban CA, Cavalli IJ and Ribeiro EM: PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer. Genet Mol Res. 14:6960–6967. 2015.PubMed/NCBI View Article : Google Scholar
33	Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H, Lieberman R, Buckanovich RJ, Lin YG and Neamati N: Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget. 8:103543–103556. 2017.PubMed/NCBI View Article : Google Scholar
34	Mao L, Wu X, Gong Z, Yu M and Huang Z: PDIA6 contributes to aerobic glycolysis and cancer progression in oral squamous cell carcinoma. World J Surg Oncol. 19(88)2021.PubMed/NCBI View Article : Google Scholar
35	Yan C, Song X, Wang S, Wang J and Li L: Knockdown of PDIA6 inhibits cell proliferation and enhances the chemosensitivity in gastric cancer cells. Cancer Manag Res. 12:11051–11062. 2020.PubMed/NCBI View Article : Google Scholar
36	Kim TW, Ryu HH, Li SY, Li CH, Lim SH, Jang WY and Jung S: PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells. J Neurosurg. 126:1829–1838. 2017.PubMed/NCBI View Article : Google Scholar
37	Bai Y, Liu X, Qi X, Liu X, Peng F, Li H, Fu H, Pei S, Chen L, Chi X, et al: PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway. EBioMedicine. 42:311–325. 2019.PubMed/NCBI View Article : Google Scholar
38	Cheng HP, Liu Q, Li Y, Li XD and Zhu CY: The inhibitory effect of PDIA6 downregulation on bladder cancer cell proliferation and invasion. Oncol Res. 25:587–593. 2017.PubMed/NCBI View Article : Google Scholar